REGION:
Get started with SVB

Are you an innovation company or investor seeking banking services to help you move bold ideas forward, fast?

Let's get started

Existing SVB clients

Get quick answers from our support page.

For help with commercial cards
1.866.553.3481
cardservices@svb.com

For other questions contact Client Service:

1.800.774.7390
clientservice@svb.com

Find a location

Technical or site issue?

Atopix Therapeutics receives a £3.25M capital term loan from Silicon Valley Bank

Client News  | 

Atopix Therapeutics Limited, a UK biopharmaceutical company developing innovative CRTH2 antagonists for Th2-mediated diseases including atopic dermatitis and severe asthma, today announced the funding of a new capital term loan from  Silicon Valley Bank, the bank of the world's most innovative businesses and their investors. The new loan provides £3.25M in additional capital to support Atopix Therapeutics' phase two clinical studies.

Atopix Therapeutics is a clinical-stage, biopharmaceutical company based in Oxford, United Kingdom. The company is focused on developing a novel class of medicines to treat TH2-mediated disease indications, including atopic dermatitis and severe asthma. Investors backing the business include SROne, Wellington Partners and SV Life Sciences.

"This new capital will support key clinical activities necessary to the development of our medicines," said Tim Edwards, the Executive Chairman of Atopix Therapeutics Limited. "Silicon Valley Bank's support of Atopix demonstrates the potential for term loan financing to add real value to a clinical stage biotech company."

Nooman Haque, Director of UK Life Sciences & Healthcare for Silicon Valley Bank, added: "Silicon Valley Bank aims to work with innovative businesses around the world that bring important medical advances to the market. We look forward to our partnership with the Atopix team as they progress through the next clinical phase and we are delighted to be working alongside this internationally recognised syndicate of investors to support Atopix."

About Silicon Valley Bank

For more than 30 years, Silicon Valley Bank (SVB) has helped innovative businesses and their investors move bold ideas forward, fast. SVB provides a range of targeted financial services and expertise through its office in the UK. With commercial and international banking services, SVB helps address the unique needs of innovators. Forbes named SVB one of America's best banks (2015) and one of America's best-managed companies (2014). In 2014, SVB was recognised as Service Provider of the Year for the third year in a row at the Investor Allstar Awards in London. SVB's life science and healthcare practice provides a range of financial services to innovative companies that are improving health through technology. Learn more at svb.com/lifescience.

Silicon Valley Bank is registered in England and Wales at 41 Lothbury, London EC2R 7HF, UK under No. FC029579. Silicon Valley Bank is authorised and regulated by the California Department of Business Oversight and the United States Federal Reserve Bank; authorised by the Prudential Regulation Authority with number 577295; and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. Silicon Valley Bank is a subsidiary of SVB Financial Group (NASDAQ: SIVB), a Delaware corporation and is an affiliate of SVB Financial Group UK Limited.

About Atopix Therapeutics Limited

Atopix Therapeutics Limited is a privately held, clinical-stage biopharmaceutical company based in Oxford, UK developing a novel class of medicines to treat Th2-mediated diseases including atopic dermatitis and severe asthma. The company is developing a class of oral medicines, called CRTH2 antagonists. Its lead candidate is currently being studied in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis in several leading European dermatology centres. The company is also assessing the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a Phase I study. Atopix has a pipeline of highly potent back-up CRTH2 antagonists, including topical candidates that can be formulated for treatment of a number of severe allergic conditions including eye disease. For more information, please visit www.atopixtherapeutics.com. 

 

Contact:
Jennifer Thompson
Silicon Valley Bank – UK Branch  
T: +44 (0)20 7367 8111
jenthompson@svb.com 

 

Now Let's Get Started

See how SVB makes next happen now for entrepreneurs like you.

Connect with Us